• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.最新进展：2型糖尿病患者对口服抗血小板治疗反应低下
Curr Cardiovasc Risk Rep. 2015 Jan;9:4. doi: 10.1007/s12170-014-0430-5.
2
Dual antiplatelet therapy in patients with diabetes mellitus: special considerations.糖尿病患者的双联抗血小板治疗：特殊考量
Expert Rev Cardiovasc Ther. 2013 Mar;11(3):307-17. doi: 10.1586/erc.13.3.
3
Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.糖尿病患者接受双联抗血小板治疗时的维生素 D 水平和血小板反应性。
Vascul Pharmacol. 2019 Sep;120:106564. doi: 10.1016/j.vph.2019.106564. Epub 2019 Jun 7.
4
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.普拉格雷与替格瑞洛在2型糖尿病合并冠状动脉疾病患者中的药效学比较：OPTIMUS（糖尿病优化抗血小板治疗）-4研究
Circulation. 2016 Sep 13;134(11):780-92. doi: 10.1161/CIRCULATIONAHA.116.023402. Epub 2016 Aug 24.
5
Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.替格瑞洛与普拉格雷对2型糖尿病合并冠心病患者的药效学作用比较。
J Clin Pharm Ther. 2018 Jun;43(3):342-347. doi: 10.1111/jcpt.12651. Epub 2017 Nov 17.
6
Ticagrelor: a novel reversible oral antiplatelet agent.替格瑞洛：一种新型可逆的口服抗血小板药物。
Cardiol Rev. 2011 Mar-Apr;19(2):95-100. doi: 10.1097/CRD.0b013e3182099d86.
7
Antiplatelet effect of aspirin in patients with coronary artery disease.阿司匹林对冠状动脉疾病患者的抗血小板作用。
Dan Med J. 2012 Sep;59(9):B4506.
8
Review of aspirin and clopidogrel resistance in peripheral arterial disease.外周动脉疾病中阿司匹林和氯吡格雷抵抗的综述。
J Vasc Surg. 2017 Nov;66(5):1576-1586. doi: 10.1016/j.jvs.2017.07.065.
9
Current Status of Antiplatelet Therapy in Acute Coronary Syndrome.急性冠状动脉综合征抗血小板治疗的现状
Cardiovasc Hematol Agents Med Chem. 2015;13(1):40-9. doi: 10.2174/187152571301150730114514.
10
Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor.心脏病学中的抗血小板药物：关于阿司匹林、氯吡格雷、普拉格雷和替格瑞洛的报告。
Curr Pharm Des. 2016;22(13):1918-32. doi: 10.2174/1381612822666151208120106.

引用本文的文献

1
Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis.替格瑞洛与氯吡格雷在2型糖尿病急性冠脉综合征患者中观察到的心血管结局：一项荟萃分析。
Diabetes Ther. 2023 Feb;14(2):387-399. doi: 10.1007/s13300-022-01354-5. Epub 2022 Dec 21.
2
Impact of Diabetes on Platelet Function in Acute Ischemic Stroke Patients Taking Dual Antiplatelet Therapy.糖尿病对接受双联抗血小板治疗的急性缺血性卒中患者血小板功能的影响。
Front Neurol. 2021 Nov 4;12:712024. doi: 10.3389/fneur.2021.712024. eCollection 2021.
3
Role of platelet-derived growth factor in type II diabetes mellitus and its complications.血小板衍生生长因子在 2 型糖尿病及其并发症中的作用。
Diab Vasc Dis Res. 2020 Jul-Aug;17(7):1479164120942119. doi: 10.1177/1479164120942119.
4
Induction of Diabetes Abolishes the Antithrombotic Effect of Clopidogrel in Apolipoprotein E-Deficient Mice.糖尿病的诱导消除了氯吡格雷在载脂蛋白E缺乏小鼠中的抗血栓形成作用。
TH Open. 2017 Aug 10;1(2):e92-e100. doi: 10.1055/s-0037-1605361. eCollection 2017 Jul.
5
Targeting aspirin resistance with nutraceuticals: a possible strategy for reducing cardiovascular morbidity and mortality.用营养保健品靶向治疗阿司匹林抵抗：一种降低心血管发病率和死亡率的可能策略。
Open Heart. 2017 Sep 2;4(2):e000642. doi: 10.1136/openhrt-2017-000642. eCollection 2017.

本文引用的文献

1
Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012.1980 年至 2012 年美国 20 至 79 岁成年人确诊糖尿病的患病率和发病率趋势。
JAMA. 2014 Sep 24;312(12):1218-26. doi: 10.1001/jama.2014.11494.
2
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.2 型糖尿病合并冠状动脉疾病患者对血小板 P2Y12 受体拮抗剂氯吡格雷反应受损。
J Am Coll Cardiol. 2014 Sep 9;64(10):1005-14. doi: 10.1016/j.jacc.2014.06.1170.
3
Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes.非高密度脂蛋白胆固醇是 2 型糖尿病肥胖患者阿司匹林抵抗的独立危险因素。
Atherosclerosis. 2014 May;234(1):146-51. doi: 10.1016/j.atherosclerosis.2014.01.015. Epub 2014 Feb 12.
4
Standards of medical care in diabetes--2014.2014年糖尿病医疗护理标准
Diabetes Care. 2014 Jan;37 Suppl 1:S14-80. doi: 10.2337/dc14-S014.
5
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会成人降低动脉粥样硬化性心血管风险的血胆固醇治疗指南：美国心脏病学会/美国心脏协会实践指南工作组报告
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12.
6
Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study.替格瑞洛与普拉格雷在伴有急性冠脉综合征的糖尿病患者中的比较。一项药效学随机研究。
Thromb Haemost. 2014 Feb;111(2):273-8. doi: 10.1160/TH13-05-0384. Epub 2013 Oct 24.
7
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.抗血小板药物治疗后反应性血小板检测用于缺血和出血事件的共识与更新：ADP 相关性。
J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73. doi: 10.1016/j.jacc.2013.07.101. Epub 2013 Sep 27.
8
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).与欧洲糖尿病研究协会（EASD）合作制定的欧洲心脏病学会（ESC）糖尿病、糖尿病前期和心血管疾病指南：欧洲心脏病学会（ESC）糖尿病、糖尿病前期和心血管疾病特别工作组与欧洲糖尿病研究协会（EASD）合作制定。
Eur Heart J. 2013 Oct;34(39):3035-87. doi: 10.1093/eurheartj/eht108. Epub 2013 Aug 30.
9
Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.在阿司匹林或氯吡格雷单药治疗的糖尿病合并冠心病患者中 EV-077 的药效学作用：一项体外初步研究结果。
J Thromb Thrombolysis. 2014;37(2):131-8. doi: 10.1007/s11239-013-0979-8.
10
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.药物洗脱支架冠状动脉植入后血小板反应性与临床结局（ADAPT-DES）：一项前瞻性多中心登记研究。
Lancet. 2013 Aug 17;382(9892):614-23. doi: 10.1016/S0140-6736(13)61170-8. Epub 2013 Jul 26.

最新进展：2型糖尿病患者对口服抗血小板治疗反应低下

State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.

作者信息

Kumbhani Dharam J, Marso Steven P, Alvarez Carlos A, McGuire Darren K

机构信息

UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9047, /

UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-, /

出版信息

Curr Cardiovasc Risk Rep. 2015 Jan;9:4. doi: 10.1007/s12170-014-0430-5.

DOI:10.1007/s12170-014-0430-5
PMID:25844111
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4382012/
Abstract

Diabetes mellitus is a global pandemic, associated with a high burden of cardiovascular disease. There are multiple platelet derangements in patients with diabetes, and antiplatelet drugs remain the first-line agents for secondary prevention as well as for high-risk primary prevention among patients with diabetes. This review provides a summary of oral antiplatelet drug hypo-responsiveness in patients with diabetes, specifically aspirin and Clopidogrel resistance. Topics discussed include antiplatelet testing, definitions used to define hypo-response and resistance, its prevalence, association with clinical outcomes and strategies to mitigate resistance. The role of prasugrel and ticagrelor, as well as investigational agents, is also discussed.

摘要

糖尿病是一种全球性的流行病，与心血管疾病的高负担相关。糖尿病患者存在多种血小板紊乱情况，抗血小板药物仍是糖尿病患者二级预防以及高危一级预防的一线用药。本综述总结了糖尿病患者口服抗血小板药物低反应性，特别是阿司匹林和氯吡格雷抵抗的情况。讨论的主题包括抗血小板检测、用于定义低反应性和抵抗的定义、其患病率、与临床结局的关联以及减轻抵抗的策略。还讨论了普拉格雷和替格瑞洛的作用以及研究性药物的作用。